Stockscreener 앱 받기
1.25
2.34%
-0.03
시간 외 거래:
1.33
0.08
+6.40%
Telomir Pharmaceuticals Inc 주식(TELO)의 최신 뉴스
Telomir Pharmaceuticals, Inc.: Telomir-Zn reverses insulin resistance in 14 days in new study - Traders Union
Exclusive: Telomir Pharmaceuticals secures FDA nod for its breast cancer therapy to advance into human study - MSN
Telomir Showcases Preclinical Telomir-Zn Diabetes Efficacy Data - TipRanks
Telomir Pharmaceuticals Publishes Peer-Reviewed Data Showing Telomir-Zn Restores Insulin Sensitivity in Type 2 Diabetes Model – Minichart - Minichart
Telomir publishes preclinical data on diabetes treatment candidate - Investing.com
Telomir publishes preclinical data on diabetes treatment candidate By Investing.com - Investing.com Canada
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model - ACCESS Newswire
Telomir (NASDAQ: TELO) adds Telomir-Zn diabetes data to support FDA-cleared TNBC trial - Stock Titan
Experimental drug candidate reversed insulin resistance in 14 days — in fish - Stock Titan
Telomir Pharmaceuticals (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Pre‑Revenue Development StageSubscription Growth Report - newsline.com
Telomir Pharmaceuticals, Inc. reveals promising anti-tumor impact with Telomir-Zn in prostate cancer study - Traders Union
Telomir Pharmaceuticals (TELO) CFO Andriy Mushak files initial Form 3 - Stock Titan
Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO - Investing.com UK
Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change - TipRanks
Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO By Investing.com - Investing.com South Africa
Telomir PharmaceuticalsAlan Weichselbaum To Step Down As CFO Effective June 6, 2026SEC Filing - TradingView
Telomir Pharmaceuticals, Inc. Announces CFO Changes, Effective June 6, 2026 - marketscreener.com
Telomir Pharmaceuticals (NASDAQ: TELO) taps consultant as new fractional CFO - Stock Titan
Telomir Pharmaceuticals (TELO) Edges Lower Amid Consolidation Near SupportTrend Following Picks - newsline.com
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer - ACCESS Newswire
TELO Stock Price, Quote & Chart | TELOMIR PHARMACEUTICALS INC (NASDAQ:TELO) - ChartMill
Telomir Pharmaceuticals (TELO) Edges Lower, Testing Support Levels Amid Low VolumeProfitability Factor - The Legal Advocate
TELO Q4 2025 Earnings: EPS Misses Estimates by 292% as Cash Burn Continues; No Revenue ReportedEPS Surprise History - newsline.com
Telomir Pharmaceuticals (TELO) Consolidates Near $1.29 as Support and Resistance Levels TightenATR Stop - The Legal Advocate
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Significant EPS Miss Amid Pre-Clinical Stage OperationsNext Quarter Guidance - The Legal Advocate
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider Than Expected Loss Highlights Pre-Revenue ChallengesCFO Commentary Report - The Legal Advocate
Telomir Pharmaceuticals Q4 2025 Earnings: Wider Than Expected Loss Highlights Clinical-Stage ChallengesAnnual Financial Report - newsline.com
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer - ACCESS Newswire
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) - ACCESS Newswire
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Development-Stage ChallengesReturn On Capital - The Legal Advocate
Telomir Pharmaceuticals (TELO) director swaps 25K options for lower $1.30 strike - Stock Titan
Telomir Pharmaceuticals (TELO) director resets 25K stock options terms - Stock Titan
Telomir Pharmaceuticals Q4 2025 Earnings: Wider-than-Expected Loss as Revenue Remains AbsentRising Community Picks - Newser
Telomir (NASDAQ: TELO) CEO reshapes 4M+ options at lower $1.30 strike - Stock Titan
Telomir Pharmaceuticals (TELO) Stock Analysis: -4.96% Down — Bearish Signals to Watch 2026-05-21Smart Money Flow Stocks - Newser
Telomir Pharmaceuticals (TELO) Q4 2025 Miss: What Went WrongQuarterly Financial Update - The Legal Advocate
Telomir Pharmaceuticals Publishes Peer-Reviewed Data Showing Telomir-Zn Improves Survival and Liver Outcomes in Wilson’s Disease Model - Minichart
Telomir Pharmaceuticals publishes peer-reviewed study on Telomir-Zn for Wilson disease - Traders Union
Telomir-Zn Preclinical Data Published in Wilson’s Disease - TipRanks
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease - ACCESS Newswire
Wilson’s disease study backs Telomir-Zn for Telomir (NASDAQ: TELO) - Stock Titan
Study links Telomir-Zn to better survival in toxic copper buildup disorder - Stock Titan
Telomir Pharmaceuticals (TELO) Q4 2025 Disappoints — EPS $-0.28 Below $-0.07 ViewsEBITDA Margin Trends - Newser
Telomir Pharmaceuticals, Inc. 1Q 2026: Revenue $0 EPS $(0.03) — 10-Q Summary - TradingView
Telomir (NASDAQ: TELO) closes TELI deal amid Q1 loss and cash risk - Stock Titan
MIRA Pharmaceuticals (MIRA) posts Q1 2026 loss and warns on going concern - Stock Titan
TradingKey - TradingKey
GLP safety trials find Telomir 1 well tolerated, Telomir Pharmaceuticals, Inc. asserts - Traders Union
EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study - Sahm
Telomir Pharmaceuticals Receives FDA Clearance for IND of Telomir-Zn in Phase 1/2 Trial for Triple-Negative Breast Cancer 8 - Minichart
Telomir Says US FDA Clears Investigational New Drug Application for Telomir-Zn to Treat Triple-Negative Breast Cancer - marketscreener.com
Telomir Pharmaceuticals Receives FDA IND Clearance for Telomir-Zn - TipRanks
Telomir Pharmaceuticals (TELO) wins FDA IND clearance for Telomir‑Zn Phase 1/2 cancer trial - Stock Titan
2.60%
0.94%
자본화:
|
볼륨(24시간):